來源: WSJ Markets ↗
Trump Administration Shift Puts This Corner of Biotech Back in Favor
|
暫時無法翻譯，請重試。
來源報導重點
With the Food and Drug Administration’s hard-liners gone, investors are rushing back into rare-disease bets.
在 WSJ Markets 閱讀原始報導 ↗